Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vibecotamab, an antibody targeting IL3RA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tidutamab, an antibody targeting SSTR2 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tamrintamab, an antibody targeting DPEP3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tabituximab, an antibody targeting FZD10.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rolinsatamab, an antibody targeting PRLR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Elipovimab, an antibody targeting HIV-1 gp120.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atoltivimab, an antibody targeting Zaire Ebolavirus Glycoprotein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vulinacimab, an antibody targeting VEGFR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Urabrelimab, an antibody targeting CD47.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tinurilimab, an antibody targeting CEACAM6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Simlukafusp, an antibody targeting FAP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Revdofilimab, an antibody targeting OX40.